Calcium and phosphorus control

Contributions to Nephrology

Volumn 145, Issue , 2004, Pages 63-68

  Lindsay, Robert M ^a   Pierratos, Andreas ^b   Lockridge, Robert S ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Lynchburg Nephrology Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; PHOSPHORUS;

BLOOD; BONE DENSITY; CALCINOSIS; CHRONIC KIDNEY FAILURE; HOMEOSTASIS; HUMAN; RENAL REPLACEMENT THERAPY; REVIEW;

BONE DENSITY; CALCINOSIS; CALCIUM; HOMEOSTASIS; HUMANS; KIDNEY FAILURE, CHRONIC; PHOSPHORUS; RENAL DIALYSIS;

EID: 16544366149     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000081669     Document Type: Article

References (26)

1. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D: Calcium, phosphate, and PTH levels in the hemodialysis population: A multicenter study. J Nephrol 2002;15:165-170.
2. Malluche HH, Monier-Faugere MC: Understanding and managing hyperphosphatemia in patients with chronic renal disease. Clin Nephrol 1999;52:267-277.
3. Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: Pathogenic and clinical aspects. Am J Kidney Dis 2001;38:S20-S33.
4. Locatelli F, Cannata-Andia JB, Drueke TB, Horl WH, Fouque D, Heimburger O, Ritz E: Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002;17:723-731.
5. Hsu CH: Are we mismanaging calcium and phosphate metabolism in renal failure? Am J Kidney Dis 1997;29:641-649.
6. Delmez J, Kaye M: Bone disease; in Daugirdas J, Blake P, Ing T (eds): Handbook of Dialysis, ed 3. Philadelphia, Lippincott Williams & Wilkins, 2001, chapt 30, pp 530-547.
7. Block GA, Port FK: Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis 2000;35:1226-1237.
8. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
9. Block GA: Prevalence and clinical consequences of elevated Ca × P product in hemodialysis patients. Clin Nephrol 2000;54:318-324.
10. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H: The progression of vascular calcification and serum osteoprotegrin levels in patients on long-term hemodialysis. Am J Kidney Dis 2003;42:303-309.
11. Chertow GM, Raggi P, McCarthy JT, Schulman G, Silberzweig J, Kuhlik A, Goodman WG, Boulay A, Burke SK, Toto RD: The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-314.
12. Chan C, Murali K, Ilumin M, Richardson R: Improvement in phosphate control with short daily in-center hemodialysis. J Am Soc Nephrol 2001;12:262A.
13. Kooistra MP, Vos J, Koomans HA, Vos PF: Daily home haemodialysis in the Netherlands: Effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 1998;13:2853-2860.
14. Mucsi I, Hercz G, Uldall R, et al: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 1998;53:1399-1404.
15. Lindsay R, Al-Hejaili F, Nesrallah G, Leitch R, Clement L, Heidenheim A, Kortas C: Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis 2003;42:S24-S29.
16. Traeger J, Galland R, Ferrier ML, Delawari E: Optimal control of phosphatemia by short daily hemodialysis. J Am Soc Nephrol 2002;13:410A-411A.
17. Lockridge RS, Albert J, Anderson H, Barger T, Coffey L, Craft V, Jennings FM, McPhatter L, Spencer M, Swafford A: Nightly home hemodialysis: Fifteen months of experience in Lynchburg, Virginia. Home Hemodial Int 1999;3:23-28.
18. Pierratos A: Nocturnal home haemodialysis: An update on a 5-year experience. Nephrol Dial Transplant 1999;14:2835-2840.
19. O'Sullivan DA, McCarthy JT, Kumar R, Williams AW: Improved biochemical variables, nutrient intake, and hormonal factors in slow nocturnal hemodialysis: A pilot study. Mayo Clin Proc 1998;73:1035-1045.
20. McPhatter LL, Lockridge RS: Nutritional advantages of nightly home hemodialysis. Nephrol News Issues 2002;16:31-33.
21. Argiles A, Mourad G: How do we have to use the calcium in the dialysate to optimize the management of secondary hyperparathyroidism? Nephrol Dial Transplant 1998;13:62-64.
22. Naveh-Many T, Rahamimov R, Livni N, Silver J: Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995;96:1786-1793.
23. Al-Hejaili F, Kortas C, Leitch R, Heidenheim AP, Clement L, Nesrallah G, Lindsay RM: Nocturnal but not short hours quotidian hemodialysis requires an elevated dialysate calcium concentration. J Am Soc Nephrol 2003;14:2322-2328.
24. Pierratos A, Hercz G, Sherrard DJ, Copland M, Ouwendyk M: Calcium, phosphorus metabolism and bone pathology on long-term nocturnal hemodialysis. J Am Soc Nephrol 2001;12:274A.
25. Lugon JR, Andre MB, Duarte ME, Rembold SM, Cruz E: Effects of in-center daily hemodialysis upon mineral metabolism and bone disease in end-stage renal disease patients. São Paulo Med J 2001;119:105-109.
26. Kim S, Goldstein M, Szabo T, Pierratos A: Resolution of massive uremic tumoral calcinosis with daily nocturnal home hemodialysis. Am J Kidney Dis 2003;41:1-7.